摘要
目的探讨新柏氏液基薄层细胞学检测（TCT）联合Cervista HPV HR筛查宫颈癌的临床价值。方法选取2014~2015年诊断宫颈癌的患者351例,以病理诊断为金标准,对比TCT、Cervista HPV HR和TCT联合Cervista HPV HR检查的结果。结果 TCT诊断为阳性的患者210例（59.83%）,Cervista HPV HR阳性患者269例（76.64%）,阳性率均明显低于病理诊断（P〈0.05）;联合检查均为阳性131例（37.32%）,均低于单项检查方法（P〈0.05）。结论 Cervista HPV HR检查筛查宫颈癌准确率相比TCT较高,二者联用能够有效提高敏感性以及阴性预测值,减少漏诊以及假阳性的可能性。
Objective To explore the clinical significance of thin - prep cytology test（TCT）combined Cervista HPV HR technique in screeening of cervical cancer. Methods A total of 351 cases in this hospital during 2014 to 2015 were diagnosed as cervical cancer,with patho-logical diagnosis as the gold standard,the TCT,Cervista HPV HR and TCT joint Cervista HPV HR were applied for checking the results. Results Positive TCT in the diagnosis of patients was 210 cases（59. 83% ）,positive Cervista HPV HR in these patients was 269 cases（76. 64% ）,and the positive rate was significantly lower than that of pathological diagnosis（ P 〈 0. 05）. Positive joint inspection had been seen in 131 cases（37.32% ）,they were lower than those of single test（ P 〈 0. 05）. Conclusion THe accurate rate of Cervista HPV HR technique in screening cervi-cal cancer is higher than that of TCT,the joint examination can effectively increase the sensitivity and negative predictive value,thus it may reduce the probability of missed diagnosis and false positive results.
出处
《临床和实验医学杂志》
2016年第13期1312-1314,共3页
Journal of Clinical and Experimental Medicine
